Aktis Oncology Expands its Board of Directors with Appointment of Nuclear Medicine Expert Ken Herrmann, MD, MBA [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
BOSTON June 13, 2024 /PRNewswire/ -- Aktis Oncology, a clinical-stage biotechnology company discovering and developing novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the appointment of Ken Herrmann , MD, MBA, to the Company's Board of Directors. "We are pleased to expand the Aktis Board of Directors with the appointment of Dr. Ken Herrmann , a distinguished figure in the field of oncologic nuclear medicine," said Matthew Roden , PhD, President and Chief Executive Officer of Aktis Oncology. "Ken's joining us on the Board is timely, given the ongoing clinical assessment of our first-in-class Nectin-4-targeted radioconjugate, and I am excited to be able to work with Ken even more closely to achieve Aktis' vision of extending the benefits of radiopharmaceuticals for new patient populations where unmet needs exist." Dr. Herrmann is a leader in the field of nuclear medicine with over a decade of experience in clinical investigation, an
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Mounjaro Drug Tirzepatide Could Treat Sleep Apnea, Study Finds [Forbes]Forbes
- Popular weight loss drug may help treat severe sleep apnea, along with improving blood pressure [MSNBC.com]MSNBC.com
- Mounjaro Drug Tirzepatide Could Treat Sleep Apnea, Study Finds [Forbes]Forbes
- Obesity drug used in Mounjaro and Zepbound may help treat dangerous sleep apnea [Yahoo! Finance Canada]Yahoo! Finance Canada
- Obesity drug used in Mounjaro and Zepbound may help treat dangerous sleep apnea [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 4/30/24 - Beat
LLY
Sec Filings
- 6/21/24 - Form 4
- 6/20/24 - Form 144
- 6/18/24 - Form 4
- LLY's page on the SEC website